Results 11 to 20 of about 3,688,287 (401)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
New England Journal of Medicine, 2021 BACKGROUND Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33.
M. Wechsler +15 more
semanticscholar +1 more source
BMC Pulmonary Medicine, 2021 Background Physical inactivity is common in severe asthma and associated with poor health outcomes. New approaches are needed to address physical inactivity in this group.
Sarah A. Hiles +4 more
doaj +1 more source
Use of the complex of models of regression for analysis of the factors that determine the severity of bronchial asthma [PDF]
, 2020 Background: According to an International Study of Asthma and Allergies in Childhood (ISAAC), the prevalence of asthma in children of 6-7 years old has increased by 10%, and at the age of 13-14 years by 16% over the last decade.
Kozhyna, Olga S., Pihnastyi, O. M.
core +2 more sources
Characteristics, phenotypes, mechanisms and management of severe asthma
Chinese Medical Journal, 2022 Severe asthma is “asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy ...
K. Chung +6 more
semanticscholar +1 more source
Phenotype overlap in the natural history of asthma
European Respiratory Review, 2023 The heterogeneity of asthma makes it challenging to unravel the pathophysiologic mechanisms of the disease. Despite the wealth of research identifying diverse phenotypes, many gaps still remain in our knowledge of the disease's complexity.
Fabio L.M. Ricciardolo +4 more
doaj +1 more source
The Endogenous Th17 Response in NO
, 2013 Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway disease.
A Abe +106 more
core +10 more sources
ERJ Open Research, 2021 There is an increasing number of new therapies for severe asthma; however, what outcomes people with severe asthma would like improved and what aspects they prioritise in new medications remain unknown.
Vanessa L. Clark +2 more
doaj +1 more source
Journal of the American Medical Association (JAMA), 2021 Importance The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear.
L. Kim +4 more
semanticscholar +1 more source
“It's like being on a roller coaster”: the burden of caring for people with severe asthma
ERJ Open Research, 2021 Introduction Family carers and significant others play a fundamental role in the well-being of people with severe asthma. This study aimed to investigate the challenges faced by family carers/significant others of people with severe asthma, to understand
Eleanor C. Majellano +4 more
doaj +1 more source
Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics
Journal of Asthma and Allergy, 2021 Purpose Current guidelines primarily use medication levels to distinguish severe asthma from other types of asthma. In addition, severe asthma must also be uncontrolled at high-intensity treatment or become uncontrolled if treatment level is decreased ...
Lina Rönnebjerg +6 more
semanticscholar +1 more source